Furthermore, it provides the strongest possible evidence using clinically relevant tumour models and treatment protocols33 that inhibiting CXCL12/CXCR4 signalling during or immediately after RTCT improves treatment response and possibly long-term disease control without increasing (and perhaps even reducing) side effects. This evidence concerns the gene CXCR4 and neoplasm.